An abbreviated review of immune abnormalities in schizophrenia

CNS Spectrums

Volumn 6, Issue 5, 2001, Pages 392-397

  Rapaport, M H ^a   Delrahim, K K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR IMMUNITY; HUMAN; HUMORAL IMMUNITY; NEUROIMMUNOLOGY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0034936545     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900021763     Document Type: Review

References (70)

1. Clinical and experimental observations on catatonia
2. The white blood cells in dementia praecox and dementia paralytica
3. Serologisch-analytische versuche mutliquoren und seren von schizophrenien
4. Autoimmunity and mental illness: Preliminary report
5. Schizophrenia as an immunological disorder demonstration of antibrain globulins by fluorescent antibody techniques
6. Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine and normetanophrine in mouse brain
7. Lupus erythematosus and the central nervous system
8. Neuroimmunologic factors in schizophrenia
9. A psychiatric staff response to acquired immune deficiency syndrome
10. Acquired immunodeficiency syndrome presenting as schizophrenia
11. Increased numbers of CD5+ B lymphocytes in schizophrenic patients
12. Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production
13. Cellular immunity in schizophrenic patients before and during neuroleptic treatment
14. Elevated levels of soluble interleukin 2 receptors in schizophrenia
15. Immunoendocrine aspects of major depression: Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol
16. Immunological states associated with schizophrenia
17. Psychoneuroimmunology and the cytokine action in the cns: Implications for psychiatric disorders
18. The interleukins-1 alpha, -1 beta, and -2 do not acutely disrupt the murine blood-brain barrier
19. Interleukin-1 alpha in blood has direct access to cortical brain cells
20. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse
21. Interleukin-6 production by astrocytes: Induction by the neurotransmitter norepinephrine
22. Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: Interaction with the cholinergic system
23. Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells
24. A role for interleukin-2 in the regulation of striatal dopaminergic function
25. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6
26. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
27. Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects
28. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia
29. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients
30. Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients
31. The role of immune function in schizophrenia: An overview
32. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness
33. Production of interferon gamma is reduced in acute schizophrenia
34. Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients
35. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness
36. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers
37. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6
38. Increased soluble interleukin 2 receptor levels in schizophrenia
39. The soluble interleukin-2 receptor: Biology, function, and clinical application
40. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia
41. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression
42. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration
43. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins
44. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia
45. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients
46. An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients
47. A preliminary analysis investigating immune activation in schizophrenia: Key topics in brain research
48. Relationship between immune and behavioral measures in schizophrenia
49. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease
50. Decreased levels of soluble intercellular adhesion molecule-1 (SICAM-1) in unmedicated and medicated schizophrenic patients
51. Elevation of CD5+ B lymphocytes in schizophrenia
52. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: Relationship to negative symptomatology
53. Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia
54. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia
55. Antibodies to heat shock proteins in schizophrenic patients: Implications for the mechanism of the disease
56. The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness
57. Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients
58. Phenothiazine induces de novo MHC class II antigen expression on thyroid epithelial cells. A new mechanism for drug-induced autoimmunity
59. Immunologic and coagulation disorders in chlorpromazine-treated patients
60. Protective effect of chlorpromazine against the lethality of interleukin 1 in adrenalectomized or actinomycin D-sensitized mice
61. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice
62. Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro
63. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock
64. Psychoimmunology: Implications for the drug treatment of psychiatric disorders
65. Cellular immunity in schizophrenic patients before and during neuroleptic treatment
66. T-cells and psychopathology in schizophrenia: Relationship to the outcome of neuroleptic therapy
67. Effects of clozapine on in vitro immune parameters: A longitudinal study in clozapine-treated schizophrenic patients
68. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine
69. Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist